← Back to Search

Topical Gel

Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis

Phase 2
Waitlist Available
Research Sponsored by Realm Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

The purpose of this study is to determine whether PR022 Topical Gels are safe and effective treatments for mild-to-moderate atopic dermatitis (AD).

Eligible Conditions
  • Atopic Dermatitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: PR022 topical gel, 0.1%Experimental Treatment1 Intervention
Applied twice daily for 28 days
Group II: PR022 topical gel, 0.05%Experimental Treatment1 Intervention
Applied twice daily for 28 days
Group III: PR022 topical gel vehiclePlacebo Group1 Intervention
Applied twice daily for 28 days

Find a Location

Who is running the clinical trial?

Realm Therapeutics, Inc.Lead Sponsor
1 Previous Clinical Trials
96 Total Patients Enrolled
Christian Peters, MD, PhDStudy DirectorRealm
~15 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top